ZIOPHARM Oncology Inc Stock News

The clinical-stage biotech saw a slight bounce-back from its lows of last week.

Equities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same []

Brokerages expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to announce earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). ZIOPHARM Oncology reported earnings of ($0.11) per share in […]

Gateway Advisory LLC bought a new stake in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,301 shares of the biotechnology companys stock, valued at approximately $28,000. Other large investors also recently added []

ZIOPHARM Oncology, Inc. (ZIOP) with the stream of -7.58% also noticed, India Orchid Island Capital, Inc. (ORC) encountered a rapid change of -2.25% in the last hour of trading session. The post Stock on the Move: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Orchid Island Capital, Inc. (NYSE:ORC) appeared first on Stocks Equity .

Price T Rowe Associates Inc. MD increased its holdings in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by 8.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 102,936 shares of the biotechnology companys stock after purchasing an additional 8,331 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in ZIOPHARM Oncology were worth $272,000 []

Charles Schwab Investment Management Inc. raised its holdings in shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,478,785 shares of the biotechnology companys stock after purchasing an additional 10,020 shares during the []

ZIOPHARM Oncology (NASDAQ:ZIOP)s stock had its hold rating reissued by analysts at HC Wainwright in a report issued on Monday, Price Targets.com reports. Several other equities research analysts have also weighed in on the company. Lake Street Capital cut their target price on ZIOPHARM Oncology from $7.00 to $3.50 and set a buy rating on []

ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report released on Saturday morning, Zacks.com reports. The firm currently has $1.75 target price on the biotechnology companys stock. According to Zacks, ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization []

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter end

Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?

The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) fell over 8% during pre-market today. This is why it happened.